Crossmark

Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma

Crossref DOI link: https://doi.org/10.1038/s41379-022-01081-z

Published Print: 2022-10

Update policy: https://doi.org/10.1016/elsevier_cm_policy

Authors

Chapel, David B. https://orcid.org/0000-0002-9733-5442
Hornick, Jason L. https://orcid.org/0000-0001-6475-8345
Barlow, Julianne

Bueno, Raphael

Sholl, Lynette M. https://orcid.org/0000-0002-9532-9735
Funding

Funding for this research was provided by:

Ovarian Cancer Research Fund Alliance (650320)

U.S. Department of Health & Human Services | NIH | National Cancer Institute (RO1 CA120528-12)

U.S. Department of Defense (W81XWH-17-1-0373)
License Information

Text and Data Mining valid from 2022-10-01
More Information

This article is maintained by: Elsevier

Article Title: Clinical and molecular validation of BAP1, MTAP, P53, and Merlin immunohistochemistry in diagnosis of pleural mesothelioma

Journal Title: Modern Pathology

CrossRef DOI link to publisher maintained version: https://doi.org/10.1038/s41379-022-01081-z

Content Type: article

Copyright: © 2022 United States & Canadian Academy of Pathology.